✦ LIBER ✦

Selecting patients for treatment with 90Y ibritumomab tiuxetan (zevalin)

✍ Scribed by Stephanie A Gregory

Book ID: 114473377
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 124 KB
Volume: 30
Category: Article
ISSN: 0093-7754
DOI: 10.1053/j.seminoncol.2003.10.004

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Radiobiology of radioimmunotherapy with

Radiobiology of radioimmunotherapy with 90Y ibritumomab tiuxetan (zevalin)

✍ M.Carmen Hernandez; Susan J Knox 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 75 KB

Educating patients about radioimmuno-the

Educating patients about radioimmuno-therapy with yttrium 90 ibritumomab tiuxetan (Zevalin)

✍ Katherine Byar 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 133 KB

Efficacy and safety of 90Y ibritumomab t

Efficacy and safety of 90Y ibritumomab tiuxetan (zevalin) radioimmunotherapy for non-Hodgkin’s lymphoma

✍ Thomas E Witzig 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 167 KB

EANM procedure guideline for radio-immun

EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with90Y-radiolabelled ibritumomab tiuxetan (Zevalin)

✍ Jan Tennvall; Manfred Fischer; Angelika Bischof Delaloye; Emilio Bombardieri; Li 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 137 KB

Radiolabeling optimization and reduced s

Radiolabeling optimization and reduced staff radiation exposure for high-dose 90Y-ibritumomab tiuxetan (HD-Zevalin)

✍ Stefano Papi; Luigi Martano; Lucia Garaboldi; Annalisa Rossi; Marta Cremonesi; C 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 399 KB

A phase 2 study of yttrium-90 ibritumoma

A phase 2 study of yttrium-90 ibritumomab tiuxetan (Zevalin) in patients with chronic lymphocytic leukemia

✍ Nitin Jain; William Wierda; Alessandra Ferrajoli; Franklin Wong; Susan Lerner; M 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB 👁 1 views

## Abstract ## BACKGROUND: Radioimmunotherapy (RIT) with radio‐labeled monoclonal antibodies to CD20 produce a high response rate in patients with relapsed lymphoma. Use of this modality in patients with chronic lymphocytic leukemia (CLL) has been hampered by the extensive marrow involvement seen